Engineered base editor with near-zero off-target effects
AccuBase® is a cytosine base editor that converts a C•G base pair into a T•A base pair in the genome. It is independently designed by Base Therapeutics and manufactured for global sales by KACTUS. It creatively embeds the deaminase inside the Cas protein to prevent random tethering of deaminase to non-target site, significantly reducing off-target occurrence while still maintaining high editing efficiency.
Leveraging our SAMS™ protein engineering and expression platform, we have developed a large-scale production process for AccuBase® base editor. We have focused on maximizing the stability, purity, and activity of our GMP-grade AccuBase®, ensuring it meets the highest quality standards in compliance with cGMP raw materials for CGT drug manufacturing.
How does AccuBase® work?
Precision editing by activating only upon accurate target binding
After forming a ribonucleoprotein (RNP) with sgRNA, the AccuBase® protein remains in a non-editing state before binding to the target DNA. The deaminase is encapsulated inside the Cas9n protein and does not interact with any non-target DNA, thus significantly reduces the risk of off-target effects. When the RNP binds to the target DNA, the conformation of AccuBase® changes, leading to the exposure of the deaminase domain and effectively editing bases within the 3-12 window range of the target site (with the first position being the farthest from the PAM) (Figure 1).
Figure 1. AccuBase® in the non-editing stage (left) and editing stage (right).
Mechanism of action
The mechanism of action of AccuBase® involves the precise editing of target DNA sequences within the 3-12 base window of the target site, leading to specific point mutations (C to T, G to A) or gene knockouts through the introduction of stop codons or alteration of splicing sites (Figure 2).
Product Performance Data
Near-zero off-target effects
Figure 3. Measurement of off-target effects by GOTI. By leveraging the GOTI (genome-wide off-target analysis by two-cell embryo injection) to measure the off-target effects throughout the whole genome, it was shown that compared to the control base editor (with 700 SNVs detected), the number of SNV obtained after editing by AccuBase® is similar to the GFP (negative control) group, suggesting a near-to-zero off-target effects of AccuBase®.
High editing activity
Figure 4. AccuBase™ RNP was electroporated into activated primary T cells. According to flow cytometry, AccuBase™ can efficiently knock out PD1, B2M, and TRAC proteins on the membrane of activated primary T cells at the protein level. For PD1 and B2M, the knockout efficiency exceeded 80%, while the knockout efficiency of TRAC reached 96%. FACS efficacy % = (positive control - KO group)/positive control* 100%.
Avoids INDEL creation
Figure 5. Compared with Cas9 protein, AccuBase™ does not produce DNA horizontal insertions and deletions (INDELs).
Avoids chromosomal translocation
Figure 6. Compared with Cas9 protein, AccuBase® does not cause chromosomal translocation.
Product Features
KACTUS offers both GMP-grade and research-grade AccuBase® as off-the-shelf catalog products. Our GMP AccuBase® Base Editor is free from animal-derived components, has greater than 80% purity, and comes with comprehensive quality control documentation as well as additional batch production records upon request. We are dedicated to supporting your applications of AccuBase® from preclinical research through commercial manufacturing, backed by our robust technical and quality support.
Learn more about our GMP quality management systems →.
Manufactured in a GMP-compliant facility
Raw materials free from animal-derived components
High purity, activity, and stability
Traceable documentation for regulatory support
Off-the-shelf catalog product
Product Specifications & Quality
Product Specifications
Both our GMP-grade and research-grade AccuBase® adhere to the following product specifications:
| Parameter | Specification |
|---|---|
| Express System | E. Coli |
| Concentration | 10mg/ml |
| Molecular Weight | 210.14kDa |
| Form | Liquid |
| Storage Buffer | 30 mM Tris, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50% Glycerol, pH8.0 |
| Storage | Store at -80 ±10°C |
Request a sample →
Quality Control Criteria
Our GMP-grade AccuBase® meets the following quality control criteria:
| Assay | Acceptance Criteria |
|---|---|
| pH | 8.0±0.5 |
| Concentration | 9.0-11.0mg/mL |
| Purity (electrophoresis) | ≥ 80.0% |
| Purity (RP-HPLC) | ≥ 88.0% |
| Purity (SEC-HPLC) | ≥ 80.0% |
| Residual DNase | Sample/Control ≤ 3.0 |
| Residual RNase | Sample/Control ≤ 3.0 |
| Residual Host Cell Protein | ≤ 100.0ng/mL |
| Residual Host Cell DNA | ≤ 200.0ng/mL |
| Endotoxin | ≤ 10.0EU/mg |
| Sterility | Negative |
| Mycoplasma | Negative |
GMP Compliance
GMP-Grade AccuBase® is produced following cGMP standards, ensuring traceability of raw materials, manufacturing processes, and QC release testing. The GMP-Grade AccuBase® is available in long-term bulk supply with high batch-to-batch consistency to ensure suitability for industrial applications. We also offer a research-grade version for a seamless transition from preclinical study to clinical/commercial CGT drug manufacturing.
Documentation Package
GMP-Grade AccuBase® comes with customizable regulatory documentation including Data Sheet, MSDS, COA, TSE/BSE statement, CoO. KACTUS has an integrative documentation system consisting of a digital quality management system, specification program, criteria support documents, and quality reports. The documentation package is customizable based on relevant regulatory filings.
Quality Management System
→ ISO13485 Accreditation
→ Digital Manufacturing Execution System (MES)
→ Process and Analytical method validation
→ Batch-to-batch stability and consistency
→ Free from antibiotic residues and raw materials of animal origin
→ Comprehensive records for batch production
→ Pharmaceutical Class A & C Clean Room
→ Validated and maintained equipment
AccuBase® ELISA kit
We have developed an AccuBase® ELISA kit for detection of residual AccuBase® in samples. The kit uses monoclonal antibodies in a sandwich ELISA and demonstrates high accuracy.
Figure 7. Example 8-point standard curve for AccuBase® ELISA kit. The quantitative range of this ELISA kit is 187.5 pg/mL - 12 ng/mL.
Figure 8. The recovery rate of the kit was analyzed by testing three AccuBase® samples with known concentrations in dilution buffer using the same AccuBase® ELISA kit. Results show that the recovery rate of various sample concentrations is between 80% and 120%, indicating high accuracy.
FAQs
Product Specifications
Our GMP-Grade AccuBase® (#GMP-KD-0001) is always manufactured according to cGMP guidelines. We also offer a research-grade version of AccuBase® (#KD-0001) that does not undergo GMP quality control testing.
AccuBase®, GMP-Grade (#GMP-KD-0001) comes with customizable regulatory documentation including Data Sheet, MSDS, COA, TSE/BSE statement, and CoO. Batch production records, batch inspection records, etc, can also be provided. Please contact us so we can learn more about your specific regulatory filings.
Compared to Cas9 and other Cas family gene editing enzymes, AccuBase® does not cause DNA double-strand breaks, does not require donor DNA, and is not dependent on the cell cycle for precise gene repair. It also does not produce INDELs and thus poses no risk of chromosomal translocations.
Compared to other cytosine base editors, its unique structural design allows editing only at the target site, with no random off-target activity, while maintaining high editing efficiency.
AccuBase® is an engineered DNA cytosine base editing protein, creatively embedding a deaminase within the Cas protein. When AccuBase® protein forms an RNP with sgRNA, it remains in a non-editing state until it binds with the target DNA. The deaminase, encased inside the Cas9n protein, does not act on any non-target DNA, significantly reducing off-target risk. When AccuBase® RNP binds to the target DNA, a conformational change in AccuBase® exposes the deaminase domain, allowing C-to-T editing within the 3-12 window range (with the first position being far from PAM).
Production Environment. GMP-grade AccuBase® is produced in our GMP manufacturing facilities, whereas research-grade is produced in non-GMP facilities.
Quality Control Testing. GMP-grade AccuBase® includes tests for appearance, concentration, purity (2100), purity (SEC-HPLC), purity (RP-HPLC), endotoxin, DNA enzyme residue, RNA enzyme residue, host protein residue, host DNA residue, sterility, and mycoplasma. Research-grade includes concentration, identification (Bis-Tris PAGE), purity (SEC-HPLC), and endotoxin.
Regulatory Documentation. GMP-grade AccuBase® includes complete method validation, process validation reports, COA, COO, non-animal source statements, stability studies, etc., supporting client project applications. Research-grade includes instruction manuals and COA, not supporting client project applications.
Both research-grade and GMP-grade have the same bacterial strain origin, same materials used in production, same production process, and consistent protein activity.
Product Usage
Gene Knockout: Through mutating start codons, introducing stop codons, and altering splice sites.
Gene Repair: Repairing pathogenic sites. Suitable for cells that can be electroporated or directly injected, including adherent cells, suspension cells, embryonic cells (fish, mice, etc.), and plant embryos (gene gun method).
AccuBase® can edit up-to three loci per current data. Please note, the overall editing efficiency will decrease for multi-gene knockout/editing.
The single guide RNA (sgRNA) scaffold for AccuBase® is the same as that used for spCas9. Designing sgRNA for gene knockout with AccuBase® involves considering editing within the 3-12 position window. A simple approach is to first search for triplet codons CAA (Gln), CAG (Gln), CGA (Arg), or TGG (Trp), and then look for suitable PAMs (NGG) nearby.
AccuBase®, designed and developed by Base Biotechnology, holds full independent intellectual property rights and foundational technology patents. Potential partners/clients interested in using AccuBase® in their projects need to discuss patent licensing matters with Base Biotechnology. The company adopts an open, flexible, and sincere approach in negotiations.
For detailed operation instructions, refer to the datasheet on kactusbio.com. For specific scientific support, contact support@kactusbio.us.
Ordering Information
You can order AccuBase® directly online via credit card or PO. Please send PO information to orders@kactusbio.us. To request a quote, please contact sales@kactusbio.us.
Research-grade AccuBase® is available in 200UG / 500UG / 1MG. GMP-Grade AccuBase® is available in 1MG. Bulk sizes are available. Please contact sales@kactusbio.us.
AccuBase®, both research-grade and GMP-grade, is an off-the-shelf product. Catalog sizes ship
next-day in the contiguous US. For international customers, please expect up to a one-week lead time. For the lead time and price of bulk orders, please contact sales@kactusbio.us.
Explore AccuBase® Products & Resources
Research-Grade AccuBase®
View our research-grade AccuBase® base editor product page.
AccuBase® ELISA Kit
View AccuBase® ELISA Kit product page to learn more or place an order.
Product Brochure
Access detailed information on AccuBase® to see how it may support your research.
Research Poster
Explore the use of AccuBase® for editing multiple genes in primary human T cells.
Request a test sample:
Related Products & Information
AccuBase® Base Editor
CRISPR Cas9 Protein
AccuBase® News & Insights
NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS
AccuBase™ Base Editor Continues to Advance NK Cell Therapies
Base Editing Technology Leads a New Chapter in Drug Development
Global Release of the First Commercial Base Editor on the Market: AccuBase™
Gene Editing News & Insights
Panorama of CRISPR Gene Editing Clinical Applications: 2024 Review
2024 Milestones in CRISPR Clinical Pipelines
IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme
Gene Editing Drugs from the EMA Review Perspective
FDA New Guidelines Pave the Way for Gene Editing Drug Development
60 Hickory Drive
Waltham, MA 02451
United States
GMP-Grade Cytosine Base Editor: AccuBase® | KACTUS